About Us
Company History
2018
2019
2020
2021
2022
2023
2024
2018 
Company Founded and Angel Investment Completed
2019 
Initiated research and development of innovative drugs for musculoskeletal diseases
2020 
Completed Series A financing
Launched phase I/II trial of innovative biologic drug AGA111 for spinal fusion
2021 
Candidate selection of two novel compounds entering into IND-enabling stage
Completed the enrollment of AGA111 Phase I/II trial
Completed Series B financing
2022 
Initiated AGA2118 first-in-human (FIH) trial
AGA2115 received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by FDA
Completed AGA111 PhI/II trial
2023 
AGA2118 FIH trial recruitment completed (SAD+MAD)
AGA2115 FIH trial in US started
Completed Series B+ financing
AGA111 Phase 3 registrational trial started
2024 
Series B extension financing completion
Management Team
Hua Zhu (David) Ke, MD
Founder, Chairman,
CEO
Willard Dere, MD, FACP
Chief Medical Officer,
Chief Advisor to CEO
Muyu (Luna) Li, MBA
Co-founder,
Chief Operating Officer
Lei Zheng, PhD
Chief Technology Officer
Xiaofeng Liu, PhD
Head of Discovery Research
Ann Zovein, MD, MBA
Head of Translational Science
Ricardo Dent, MD
Head of Global Clinical Development
Tom Storey, MBS, MBA
Head of Business Development
Our Vision
Innovation for patients
Our Mission
Our mission is to discover, develop, and commercialize breakthrough therapeutics that address large unmet medical needs of patients with serious musculoskeletal diseases.
Our Values
Integrity·Collaboration·Innovation
×